A share price of Design Therapeutics Inc [DSGN] is currently trading at $7.76, up 4.44%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DSGN shares have gain 24.36% over the last week, with a monthly amount glided 19.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Design Therapeutics Inc [NASDAQ: DSGN] stock has seen the most recent analyst activity on May 07, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $12 from $6. Previously, Piper Sandler downgraded its rating to Neutral on November 14, 2023, and dropped its price target to $6. On August 15, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $6 on the stock. SVB Securities downgraded its rating to a Market Perform but stick to its price target of $6 on August 15, 2023. RBC Capital Mkts downgraded its rating to a Sector Perform and reduced its price target to $7 on August 15, 2023. Goldman upgraded its rating to Neutral for this stock on May 04, 2023, but kept the price target unchanged to $6. In a note dated June 10, 2022, Wedbush initiated an Outperform rating and provided a target price of $21 on this stock.
Design Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $2.60 and $7.93. Currently, Wall Street analysts expect the stock to reach $9.67 within the next 12 months. Design Therapeutics Inc [NASDAQ: DSGN] shares were valued at $7.76 at the most recent close of the market. An investor can expect a potential return of 24.61% based on the average DSGN price forecast.
Analyzing the DSGN fundamentals
Gross Profit Margin for this corporation currently stands at -0.29% with Operating Profit Margin at -127.43%, Pretax Profit Margin comes in at -107.97%, and Net Profit Margin reading is -107.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.27 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.41 points at the first support level, and at 7.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.94, and for the 2nd resistance point, it is at 8.13.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Design Therapeutics Inc [NASDAQ:DSGN] is 18.71. In addition, the Quick Ratio stands at 18.71 and the Cash Ratio stands at 2.25.
Transactions by insiders
Recent insider trading involved Logos Global Master Fund LP, Director, that happened on Nov 07 ’25 when 0.41 million shares were purchased. Director, William Arsani completed a deal on Aug 13 ’25 to sell 0.56 million shares. Meanwhile, Director Logos Opportunities Fund II LP bought 0.22 million shares on Aug 13 ’25.
